Spatial temporal map of glioma cancer cells
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Figure 3. Immunohistochemical analysis of the xenograft
tumor sections with pERK (downstream component of the
RAF/MEK/ERK signaling pathway), pAKT (downstream
component of the AKT signaling pathway) and Ki67
(proliferation) staining. Control: Antibody negative control
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Brain tissues were fixed in 4% paraformaldehyde for 24
hours, embedded in paraffin, serially cut into 4-μm
sections, and stained with H&E (Sigma-Aldrich,
St.Louis, MO, USA).
For immunohistochemical stains, the tumor sections
were deparaffinized and subjected to graded
rehydration. After blocking the sections in 2.5% serum
and performing antigen retrieval (citrate buffer, pH 6.0),
we incubated the sections with the primary antibodies
overnight at 4°C.
Following, we incubated with secondary antibody and
used Signal Stain DAB Substrate Kit, brown stain
reveals positively stained human GBM. The cells were
counterstained with hematoxylin. The slides were
subjected to graded dehydration, and we mounted using
DPX.
Immunofluorescence staining was performed using
primary antibody and then we incubated the sections
with secondary antibodies We then incubated the
sections with Texas red fluorescein isothiocyanate–
conjugated secondary antibodies and green fluorescein
isothiocyanate–conjugated secondary antibodies for 120
minutes at room temperature.
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Expression of Ki-67 in trametinib
treated mouse xenografts
Figure 1. Immunohistochemical analysis celullar phenotype in
human GBM tumor paraffin sections. Representative 40X
images of IHC staining for olig2 (proneural stem cell marker),
CD44 (mesenchymal stem cell marker), SOX9 (EGFR positive
cancer cell marker), GFAP (astrocyte marker) and ETV5 (EGFR
positive cancer cell marker).
a Control: Antibody negative control.
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Glioblastoma (GBM) is the most common aggressive,
lethal brain tumor in adults.
GBM is highly heterogeneous and disease
progression is attributed to several factors, including
the tumor microenvironment, perturbation in signaling
pathways, metabolic alterations, and epigenetic
modifications.
The objectives of this study is to determine the
cellular phenotype and expression levels of ETV5,
an important glial lineage transcription factor that
plays a role in tumor growth.
In addition, we also aimed to determine the signaling
pathways affected by MEK inhibition (indirectly
blocking ETV5) in mouse xenograft tumors.
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Expression of CNS cell markers in
FFPE human glioma tissue sections
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Conditions for optimal staining were established
for most cellular phenotype markers such as
SOX9 and ETV5 as EGFR positive cancer cell
markers, general astrocyte marker GFAP.
To discriminate between glioma molecular
subtypes, we optimized olig2 as proneural and
CD44 as mesenchymal. Furthermore, we
optimized the staining conditions for proliferative
and signaling markers for mouse xenograft
tumors. Ongoing studies will establish the use of
these antibodies to develop a multiplex antibody
panel of cellular phenotype markers to determine
the spatial temporal expression of cellular
composition of glioma tissues.

Conclusion
This study will aid the development and
standardization of a panel of multiplex
immunofluorescence antibodies to construct a
spatial and temporal map of glioma cancer cells
and their cellular composition in a single tissue
section.
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Figure 4. Immunohistochemical analysis of Ki67 (proliferation
marker) in mouse xenograft tumors treated with and without
trametinib (MEK inhibitor drug with anti-cancer activity).
Control: Antibody negative control
Figure 2. FFPE human glioma tissue sections stained with (a)
DAPI, (b) GFP (CD44), (c) Texas Red (ETV5) and (d) merged
fluorescent image
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